Precision Medicine Market Size, Share, And Trends - Global Forecast 2026-2032 AI, Genomics, And Companion Diagnostics Drive 13.34% CAGR Toward USD 324.92 Billion


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI with validated biomarkers, AI-ready data, companion diagnostics, payer evidence, inclusive trials, cybersecurity and cross-sector partnerships.

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Precision Medicine Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

This market research report examines the global precision medicine market, which is projected to reach USD 152.68 billion in 2026 and expand at a CAGR of 13.34% to USD 324.92 billion by 2032. It analyzes the shift from population-based healthcare toward biomarker-driven therapies, genomic testing, companion diagnostics, pharmacogenomics, molecular imaging, and data-enabled clinical decision support.

Market Overview and Growth Drivers

Precision medicine aligns prevention, diagnosis, and treatment with each patient's biological, environmental, and lifestyle characteristics. Adoption is strongest across oncology, rare diseases, immunology, cardiology, neurology, and infectious diseases, where validated biomarkers increasingly guide treatment selection and monitoring.

Major initiatives-including NIH All of Us, the UK 100,000 Genomes Project, Genome India, Gulf national genome programs, and Europe's 1+ Million Genomes framework-demonstrate growing institutional commitment. The report's market forecasts and adoption analysis support strategic planning, investment prioritization, and opportunity identification across healthcare and life sciences.

Transformative Market Shifts

The industry is progressing from isolated genetic tests to integrated ecosystems combining multi-omics, real-world evidence, electronic health records, imaging, wearable data, and longitudinal monitoring. Key growth technologies include:

  • Next-generation sequencing and liquid biopsy
  • Companion diagnostics and pharmacogenomics
  • Decentralized and adaptive clinical trials
  • Cloud-based data platforms and privacy-preserving analytics
  • Interoperable clinical decision-support systems

Regulators increasingly support biomarker-based drug development, while payers demand evidence of clinical utility, cost-effectiveness, and equitable access. These insights enable organizations to anticipate commercialization risks and align product development with evolving regulatory and reimbursement expectations.

Artificial Intelligence in Precision Medicine

Artificial intelligence is generating value across genomics, transcriptomics, proteomics, pathology, radiology, claims data, and clinical documentation. Applications include variant interpretation, patient stratification, drug-target discovery, clinical trial matching, adverse-event prediction, and treatment-response forecasting.

Successful deployment depends on curated datasets, clinician oversight, model transparency, bias testing, cybersecurity, and continuous monitoring. Federated learning, synthetic data, and privacy-enhancing technologies are also enabling collaboration while protecting sensitive patient information.

Regional and Economic Group Insights

  • North America: Leads through mature genomics infrastructure, established biomarker pathways, research networks, and strong biopharma investment.
  • Europe: Benefits from national sequencing programs, academic medicine, cross-border research, GDPR-led governance, and the European Health Data Space.
  • Asia-Pacific: Expands rapidly through genomic medicine, oncology diagnostics, digital hospitals, and population health initiatives.
  • Latin America: Builds capacity through cancer genomics, biobanking, academic partnerships, and private laboratory expansion.
  • Middle East and Africa: Growth is supported by Gulf genome programs, precision oncology investment, infectious disease genomics, newborn screening, and efforts to improve genomic representation.

ASEAN offers an emerging growth corridor, while the GCC stands out for government-backed genomics and AI investment. BRICS markets provide population scale and sequencing potential, whereas the G7 leads in diagnostics, regulatory science, AI governance, and biopharma innovation. Comparative regional intelligence can inform market-entry strategies and partnership selection.

Country-Level Highlights

The United States leads in research funding, commercial testing, regulatory guidance, and biopharma pipelines. Canada, Mexico, and Brazil are advancing through research networks, laboratory modernization, cancer genomics, and rare disease programs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong genomic and clinical research capabilities. China, India, Japan, Australia, and South Korea are expanding sequencing, digital healthcare, oncology innovation, pharmacogenomics, and AI-enabled care.

Strategic Priorities for Industry Leaders

  • Validate biomarkers and demonstrate measurable clinical utility.
  • Develop interoperable, AI-ready data architecture.
  • Expand companion diagnostic access and physician education.
  • Design inclusive clinical trials representing diverse populations.
  • Strengthen cybersecurity and privacy governance.
  • Build partnerships across biopharma, diagnostics, providers, payers, regulators, and technology companies.

Key Takeaways from This Report

  • The market is forecast to reach USD 324.92 billion by 2032.
  • Genomics, AI, companion diagnostics, and integrated health data are central growth drivers.
  • Clinical validation, reimbursement readiness, and equitable access remain critical adoption requirements.
  • Regional opportunities vary significantly by infrastructure, regulation, investment, and data governance maturity.
  • Cross-sector partnerships and responsible AI deployment will shape long-term competitive advantage.

Key Attributes:

Report Attribute Details
No. of Pages 194
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $152.68 Billion
Forecasted Market Value (USD) by 2032 $324.92 Billion
Compound Annual Growth Rate 13.3%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Precision Medicine Market, by Product Type
7.1. Introduction
7.2. Diagnostics
7.2.1. Companion Diagnostics
7.2.2. Genetic Testing
7.2.3. Liquid Biopsy
7.2.4. Molecular Diagnostics
7.2.5. Point-of-Care Testing
7.3. Software & Data Analytics
7.4. Therapeutics
7.4.1. Cell Therapy
7.4.2. Gene Therapy
7.4.3. Immunotherapy
7.4.4. Protein Replacement Therapy
7.4.5. RNA-Based Therapy
7.4.6. Targeted Therapy
8. Precision Medicine Market, by Biomarker Type
8.1. Introduction
8.2. Genomic Biomarkers
8.3. Proteomic Biomarkers
8.4. Metabolomic Biomarkers
8.5. Epigenetic Biomarkers
9. Precision Medicine Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Injectable
9.4. Intravenous
9.5. Subcutaneous
10. Precision Medicine Market, by Application
10.1. Introduction
10.2. Autoimmune Diseases
10.3. Cardiology
10.4. Infectious Diseases
10.5. Neurology
10.6. Oncology
10.7. Rare & Genetic Disorders
10.8. Respiratory Diseases
11. Precision Medicine Market, by End User
11.1. Introduction
11.2. Biopharmaceutical & Biotechnology Companies
11.3. Diagnostic Laboratories
11.4. Hospitals & Clinics
11.5. Research Institutes
12. Precision Medicine Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Precision Medicine Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Precision Medicine Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Aranscia, LLC
16.4. AstraZeneca PLC
16.5. biocrates life sciences ag
16.6. bioMerieux S.A.
16.7. Bristol-Myers Squibb Company
16.8. Caris Life Sciences
16.9. Exact Sciences Corporation
16.10. F. Hoffmann-La Roche AG
16.11. Gilead Sciences, Inc.
16.12. Guardant Health, Inc.
16.13. healthOme, Inc.
16.14. Hitachi High-Tech Corporation
16.15. Illumina, Inc.
16.16. Johnson & Johnson
16.17. Laboratory Corporation of America Holdings
16.18. Medtronic PLC
16.19. Merck KGaA
16.20. N-Power Medicine, Inc.
16.21. Natera Inc.
16.22. NeoGenomics, Inc.
16.23. Novartis AG
16.24. Pfizer, Inc.
16.25. Precision Medicine Group, LLC
16.26. QIAGEN N.V.
16.27. Quest Diagnostics Incorporated
16.28. Sanofi SA
16.29. Strata Oncology, Inc.
16.30. Tempus AI, Inc.
16.31. Teva Pharmaceutical Industries Ltd.
16.32. Thermo Fisher Scientific Inc.
16.33. ZS Associates, Inc.
17. Key Experts

List of Figures [21]
List of Tables [327]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112026004107003653ID1111990323


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search